ERAS-007 + Encorafenib + Cetuximab + Palbociclib
Phase 1/2Active 0 watching 0 views this week💤 Quiet
38
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Colorectal Cancer
Conditions
Metastatic Colorectal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
Trial Timeline
Sep 20, 2021 → Dec 1, 2025
NCT ID
NCT05039177About ERAS-007 + Encorafenib + Cetuximab + Palbociclib
ERAS-007 + Encorafenib + Cetuximab + Palbociclib is a phase 1/2 stage product being developed by Erasca for Metastatic Colorectal Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05039177. Target conditions include Metastatic Colorectal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma.
Hype Score Breakdown
Clinical
13
Activity
8
Company
7
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05039177 | Phase 1/2 | Active |
Competing Products
20 competing products in Metastatic Colorectal Cancer